Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 3 3Phase 4 2Phase 1 2Phase NA 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

romidepsin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Vincristine 4Gemcitabine 4Doxorubicin 4Cyclophosphamide 4Prednisone 3Lenalidomide 3Azacitidine 310-propargyl-10-deazaaminopterin 3pembrolizumab 2ixazomib 2fludarabine phosphate 2copanlisib 2Whole-Body Irradiation 2Vitamin B 12 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Folic Acid 2Etoposide 2Dexamethasone 2Cyclosporine 2Bortezomib 2venetoclax 1tislelizumab 1tazemetostat 1relatlimab 1prednisolone phosphate 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Peripheral × Gemcitabine × Clear all
NCT05105412 2024-07-08

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

National Health Research Institutes, Taiwan

Phase 1/2 Terminated
12 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

Peking Union Medical College Hospital

Phase 1/2 Unknown
60 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Chonnam National University Hospital

Phase 1/2 Completed
28 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡